{"cell_penetration_of_oxadiazole_containing_macrocycles.pdf": "\ud83d\udcc4 Summary of the Publication\nThe consolidated summary of the main themes identified across the provided documents is as follows:\n\n1. **Cell Penetration Mechanisms**: The research highlights the mechanisms by which cyclic peptides and macrocycles penetrate cell membranes, emphasizing the roles of passive permeability and active transport. Understanding these mechanisms is crucial for effective drug design, particularly for compounds that may have good cell penetration despite poor passive permeability.\n\n2. **Influence of Molecular Structure**: A key theme is the impact of molecular structure on biological activity and permeability. Factors such as polar surface area, hydrogen bonding, and specific structural modifications (e.g., N-methylation, incorporation of heterocycles) are critical determinants of cell penetration capabilities and overall bioavailability.\n\n3. **Conformational Dynamics**: The importance of molecular conformation is underscored, with studies utilizing techniques like NMR spectroscopy to analyze the structural characteristics of cyclic peptides. The rigidity and flexibility of these compounds significantly affect their interactions with biological membranes.\n\n4. **Design and Synthesis of Peptides**: The documents emphasize the rational design and synthesis of cyclic peptides and macrocycles, including the exploration of synthetic libraries and modifications aimed at enhancing therapeutic properties. The complexity of designing effective compounds is acknowledged, with attention to how structural substitutions can lead to unpredictable effects.\n\n5. **Experimental Techniques and Data Analysis**: Various analytical methodologies, including CAPA, PAMPA, and NMR, are employed to assess permeability and structural properties. The use of statistical analysis to ensure the reliability of experimental results is also noted, highlighting a rigorous approach to research.\n\n6. **Therapeutic Applications and Drug Development**: The overarching goal of the research is to inform drug discovery and development, focusing on optimizing cyclic peptides and macrocycles for therapeutic use. The findings provide guidelines for future research directions and emphasize the need for a comprehensive understanding of the relationship between molecular structure, transport mechanisms, and biological activity.\n\n7. **Innovations in Peptide Engineering**: The design and synthesis of engineered peptides, such as stapled peptides and those incorporating specific motifs (e.g., RGD for cell adhesion), are emphasized for their potential therapeutic roles in various biological processes.\n\nOverall, these themes reflect a multifaceted approach to understanding and optimizing cyclic peptides and macrocycles in medicinal chemistry, with a strong emphasis on their permeability, structural dynamics, and potential therapeutic applications.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nCell Penetration/Molecular Structure/Bioavailability/Conformational Dynamics/Peptide Design/Analytical Methodologies/Drug Development/Peptide Engineering/Medicinal Chemistry\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: 22,23The chloroalkane penetration assay (CAPA) is a relatively recent methodology for measuring cell penetration in live cells (Fig. 1d).\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: 22,23The chloroalkane penetration assay (CAPA) is a relatively recent methodology for measuring cell penetration in live cells (Fig. 1d).\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: acknowledges financial support from Natural Science and Engineering Research Council of Canada.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "Correction_to_Up-regulation_of_autophagy_is_a_mechanism_of_resistance_to_chemotherapy_and_can_be_inhibited_by_pantoprazole_to_increase_drug_sensitivity.pdf": "\ud83d\udcc4 Summary of the Publication\nThe consolidated summary of the main themes identified in the provided documents is as follows:\n\n1. **Scientific Integrity and Correction**: The documents emphasize the importance of accuracy in scientific publishing, highlighting a correction made to a previously published article on cancer chemotherapy. This underscores the need for rigorous data verification and accountability among researchers.\n\n2. **Chemotherapy Resistance Mechanisms**: The research focuses on understanding chemotherapy resistance, particularly the role of autophagy in cancer cells' ability to evade treatment. The correction notes that pantoprazole may inhibit this up-regulation, suggesting a potential strategy to enhance drug sensitivity.\n\n3. **Pharmacological Exploration**: The documents discuss various chemotherapy drugs and their combinations, exploring their pharmacological effects and mechanisms of action. This includes experimental data from in vitro studies using specific cancer cell lines.\n\n4. **Combination Therapy Investigations**: The research investigates the effectiveness of combination therapies, indicating a focus on optimizing treatment outcomes through drug pairings.\n\n5. **Transparency and Collaboration**: The authors' willingness to take responsibility for the error and provide contact information reflects a commitment to transparency and collaboration in the scientific community.\n\n6. **Formal Publication Standards**: The inclusion of a publisher's note highlights the importance of neutrality and accuracy in scientific reporting, reinforcing the need for high standards in the dissemination of research findings.\n\nOverall, the documents collectively stress the significance of maintaining scientific rigor, addressing errors, and advancing treatment strategies in cancer research.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nScientific Integrity/Chemotherapy Resistance/Autophagy/Pharmacology/Combination Therapy/Transparency/Publication Standards/Cancer Research\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "Assessment_of_chemistry_knowledge_in_large_language_models_that_generate_code.pdf": "\ud83d\udcc4 Summary of the Publication\nThe final consolidated summary of the main themes identified across the provided documents is as follows:\n\n1. **Advancements in Large Language Models (LLMs)**: Significant progress has been made in LLMs, particularly in their capabilities for natural language processing (NLP), few-shot learning, and code synthesis. These advancements highlight their potential applications across various fields, especially in chemistry.\n\n2. **Integration of AI in Chemistry**: The intersection of AI and chemistry is a focal point, with LLMs being utilized to generate chemical structures (e.g., SMILES notation) and predict molecular properties. This underscores the transformative impact of NLP technologies in scientific research and education.\n\n3. **Evaluation Methodologies**: The importance of systematic evaluation of LLMs is emphasized, including the role of prompt engineering in optimizing model performance. Human feedback and rigorous assessment methods are crucial for refining outputs and understanding model limitations.\n\n4. **Limitations and Challenges**: While LLMs demonstrate impressive capabilities, they also face challenges, particularly in reasoning about complex tasks and generating accurate outputs. The documents highlight the need for careful consideration of these limitations in practical applications.\n\n5. **Ethical Considerations**: Ethical implications and potential risks associated with deploying LLMs are discussed, emphasizing the need for responsible use and awareness of biases inherent in these technologies.\n\n6. **Open Access and Collaborative Research**: The theme of open access publishing and research collaboration is prevalent, promoting accessibility and knowledge sharing within the academic community. This includes the use of Creative Commons licenses to facilitate non-commercial sharing.\n\n7. **Interdisciplinary Engagement**: The documents reflect a collaborative spirit in research, drawing contributions from fields such as computer science, chemistry, and linguistics. Social media is highlighted as a platform for community engagement and discourse on AI advancements.\n\n8. **Innovative Training Techniques**: Discussions on innovative training methods, such as reinforcement learning from human feedback, aim to improve model alignment with human intentions and enhance usability in practical applications.\n\nOverall, these themes illustrate the dynamic landscape of AI and machine learning, particularly in the context of language models, their applications in scientific domains, and the ethical and collaborative considerations that accompany their development and deployment.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nMachine Learning/NLP/Chemistry/Ethics/Interdisciplinary Research\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: To evaluate this, we introduce an expandable framework for evaluating chemistry knowledge in these models, through prompting models to solve chemistry problems posed as coding tasks.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: R35GM138312 (to G. M. H.). HAG was supported by NSF award 1751471. MA, SC, and Z. Y. were supported by NIH awardR35GM137966. G. P. W. was supported by NSF award 1764415. S.S. and Y. S. were partially supported by NIH award R35GM138312,WJPC by R35GM138312-02S1, and K. L. partially by Departmentof Energy award DESC0020464. S. S. and K. L. were also partiallysupported by the Simons Foundation Grant No. 839534.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "closing_the_execution_gap_in_generative_ai_for_chemicals_and_materials_freeways_or_safeguards.pdf": "\ud83d\udcc4 Summary of the Publication\nThe consolidated summary of the main themes regarding the application of generative AI in chemistry and materials science encompasses the following key areas:\n\n1. **Generative AI and Molecular Design**: Generative AI techniques are pivotal for the design, synthesis, and optimization of novel chemicals and materials. This includes methodologies such as inverse molecular design and reaction pathway planning, leveraging deep learning models to predict properties and enhance synthesis processes.\n\n2. **Machine Learning and Data-Driven Approaches**: The integration of machine learning and data-driven methodologies, including Bayesian optimization and automated information extraction, is emphasized as essential for improving predictive capabilities and streamlining research workflows in chemistry and materials science.\n\n3. **Interdisciplinary Collaboration**: Effective application of AI in these fields requires collaboration among chemists, data scientists, and engineers, reflecting a multidisciplinary approach to address complex scientific challenges and enhance innovation.\n\n4. **Ethics, Safety, and Governance**: There is a strong focus on the ethical implications, safety measures, and governance frameworks surrounding AI technologies. This includes the need for responsible AI practices, regulatory frameworks, and safeguards to prevent misuse and unintended consequences.\n\n5. **Real-World Applications**: Practical applications and case studies demonstrate the successful implementation of AI methodologies in areas such as drug discovery and materials development, validating the transformative potential of these technologies.\n\n6. **Challenges and Limitations**: Concerns regarding the validity, reliability, and potential misuse of AI-generated outputs are highlighted, underscoring the necessity for rigorous evaluation and empirical validation of AI methodologies in scientific research.\n\n7. **Technological Advances**: Ongoing research into advanced AI methodologies, such as equivariant neural networks and automated synthesis platforms, aims to enhance the efficiency and scalability of AI applications in chemistry and materials science.\n\nOverall, these themes reflect the significant impact of generative AI and machine learning on advancing research in chemistry and materials science, while also addressing the ethical considerations and collaborative efforts required for responsible innovation.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nGenerative AI/Molecular Design/Deep Learning/Inverse Molecular Design/Reaction Pathway Planning/Machine Learning/Data-Driven Approaches/Bayesian Optimization/Automated Information Extraction/Interdisciplinary Collaboration/Ethics/Safety/Governance/Drug Discovery/Materials Development/Equivariant Neural Networks/Automated Synthesis Platforms\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: \"Scaling Deep Learning for Materials Discovery.\"\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: experimentation;[10] and the concept of AI-guided closed-loop discovery, integrated with autonomous experimentation, has been demonstrated in multiple proofs of concept (Figure 2).[11],[12],[13],[14]\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: \u201cDataset of Gold Nanoparticle Sizes and Morphologies Extracted from Literature-Mined Microscopy Images.\u201d\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "reactive_carbon_capture_enables_co2_electrolysis_with_liquid_feedstocks.pdf": "\ud83d\udcc4 Summary of the Publication\nThe main themes of the documents revolve around the electrochemical reduction and conversion of carbon dioxide (CO2), with a focus on the development of reactive carbon electrolyzers for capturing and utilizing CO2. The documents discuss challenges, advancements, and strategies for improving the efficiency and performance of electrolyzers, as well as the production of valuable chemicals and fuels from CO2. Membrane technologies, electrode design, electrolyte compositions, and energy efficiency considerations are also highlighted in the research. Overall, the documents provide insights into the potential of CO2 conversion technologies and their applications in addressing global CO2 emissions and producing valuable products.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nElectrochemical Reduction/Carbon Dioxide Conversion/Reactive Carbon Electrolyzers/Membrane Technologies/Electrode Design/Electrolyte Compositions/Energy Efficiency/CO2 Emissions/Valuable Chemicals and Fuels\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "ru_doped_functional_porous_materials_for_electrocatalytic_water_splitting.pdf": "\ud83d\udcc4 Summary of the Publication\nThe main themes from the provided documents focus on research and development in alternative energy technologies, particularly in the field of electrocatalysis for water splitting. Key areas of interest include hydrogen evolution catalysts, electrode wettability for improved mass transfer, materials for PEM electrolyzers, transition-metal-based electrocatalysts, and the use of nanostructured materials. Other topics include metal-organic frameworks, single-atom catalysis, nanoparticle-supported catalysts, nitrogen-doped carbon materials, and interface engineering for enhanced catalytic activity. The documents also discuss the synthesis and characterization of nanomaterials, such as ruthenium-based catalysts and two-dimensional materials, for efficient electrocatalysis, as well as the use of COFs and porous organic materials for catalytic applications.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nAlternative Energy Technologies/Electrocatalysis/Water Splitting/Hydrogen Evolution Catalysts/Electrode Wettability/PEM Electrolyzers/Transition-Metal-Based Electrocatalysts/Nanostructured Materials/Metal-Organic Frameworks/Single-Atom Catalysis/Nanoparticle-Supported Catalysts/Nitrogen-Doped Carbon Materials/Interface Engineering/Nanomaterials Synthesis/Ruthenium-Based Catalysts/Two-Dimensional Materials/COFs/Porous Organic Materials\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: Defect-assisted anchoring of Pt single atoms on MoS2 nanosheets produces high-performance catalyst for industrial hydrogen evolution reaction.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "AGENT-BASED_LEARNING_OF_MATERIALS_DATASETS_FROM_SCIENTIFIC_LITERATURE.pdf": "\ud83d\udcc4 Summary of the Publication\nThe main themes identified in the set of summaries revolve around the use of machine learning, artificial intelligence, and natural language processing in materials discovery and scientific literature analysis. Key topics include the development and evaluation of AI agents like Eunomia for autonomous dataset creation, information extraction tasks, and performance benchmarking. The importance of structured datasets, domain-specific toolkits, and the application of large language models in tackling complex NLP tasks are also highlighted. Additionally, there is a focus on extracting structured data from unstructured scientific literature for machine learning purposes, particularly in the context of materials science and chemistry. Other themes include water stability of materials, crystallography databases, and the role of AI agents in extracting domain-specific information from complex text.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nMachine Learning/Artificial Intelligence/Natural Language Processing/Materials Discovery/Scientific Literature Analysis/Autonomous Dataset Creation/Information Extraction/Performance Benchmarking/Structured Datasets/Domain-Specific Toolkits/Large Language Models/Unstructured Data Extraction/Materials Science/Chemistry/Water Stability/Crystallography Databases\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: An illustrative example is the case of stability of materials, where thermal, mechanical, and chemical stabilities might be confused by the agent.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: Research reported in this work was supported by the Acceleration Consortium at the University of Toronto. SMM acknowledges the support by the Natural Sciences and Engineering Research Council of Canada (NSERC) under grant\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: For this case study, we created a hand-labeled dataset based on a selection of 101 materials research papers, which contain a selection of 371 MOFs.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "synergistic_effects_of_thermosensitive_liposomal_doxorubicin_mild_hyperthermia_and_radiotherapy_in_breast_cancer_management_an_orthotopic_mouse_model_study.pdf": "\ud83d\udcc4 Summary of the Publication\nThe documents discuss the use of thermosensitive liposomes, mild hyperthermia, and radiotherapy in combination therapy for breast cancer treatment. They highlight the benefits of synergistic effects, such as enhanced drug delivery, tumor sensitization to radiation, and potential abscopal effects. The studies focus on the development and evaluation of thermally triggered drug delivery systems, the impact of hyperthermia on treatment efficacy, and the importance of multi-modal therapeutic strategies in reducing metastatic risk. Additionally, they address concerns related to cardiotoxicity, treatment toxicity, and the need for further research on the combined use of heat-activated drug delivery and radiotherapy in cancer management.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nThermosensitive Liposomes/Mild Hyperthermia/Radiotherapy/Synergistic Effects/Drug Delivery/Tumor Sensitization/Abscopal Effects/Thermally Triggered Drug Delivery/Hyperthermia/Treatment Efficacy/Multi-modal Therapeutic Strategies/Metastatic Risk/Cardiotoxicity/Treatment Toxicity/Heat-Activated Drug Delivery/Cancer Management\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: This study was supported by a CIHR project grant to C.A.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: Liposome formulations of the cancer drug doxorubicin have been developed to address the severe side effects that result\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "quest_self_supervised_skill_abstractions_for_learning_continuous_control.pdf": "\ud83d\udcc4 Summary of the Publication\nThe main themes in the list of documents focus on advancements in machine learning and robotics, covering topics such as robot learning, imitation learning, reinforcement learning, skill acquisition, image synthesis, behavior generation, visuomotor policies, language-guided skill acquisition, transformer models, mobile manipulation, teleoperation, lifelong learning, knowledge transfer, visual instruction tuning, latent action planning, hierarchical planning, continuous control tasks, scalar quantization, VQ-VAE, generalist robot policies, retrieval and alignment in robot manipulation, visual reasoning, autonomous land vehicles, neural networks, language understanding, generative pre-training, transferable visual models, causal imitation learning, multimodal models, generative models for audio, neural discrete representation learning, attention mechanisms, continual imitation learning, trajectory diffusion, keypose prediction, benchmarking for multi-task and meta reinforcement learning, 3D diffusion policy, and segmenting tasks. The documents also discuss the comparison and evaluation of models such as ResNet-T, ACT, Diffusion Policy, PRISE, VQ-BeT, and QueST in multitask imitation learning and robotic manipulation tasks, highlighting their performance metrics, success rates, and visualization techniques across different environments.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nMachine Learning/Robotics/Imitation Learning/Reinforcement Learning/Skill Acquisition/Image Synthesis/Behavior Generation/Visuomotor Policies/Language-Guided Skill Acquisition/Transformer Models/Mobile Manipulation/Teleoperation/Lifelong Learning/Knowledge Transfer/Visual Instruction Tuning/Latent Action Planning/Hierarchical Planning/Continuous Control Tasks/Scalar Quantization/VQ-VAE/Generalist Robot Policies/Retrieval and Alignment/Visual Reasoning/Autonomous Land Vehicles/Neural Networks/Language Understanding/Generative Pre-Training/Transferable Visual Models/Causal Imitation Learning/Multimodal Models/Generative Models for Audio/Neural Discrete Representation Learning/Attention Mechanisms/Continual Imitation Learning/Trajectory Diffusion/Keypose Prediction/Benchmarking/Multi-Task Learning/Meta Reinforcement Learning/3D Diffusion Policy/Segmenting Tasks\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: We validate the proposed architecture by ablating some of its key design decisions.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501", "ansari-white-2023-serverless-prediction-of-peptide-properties-with-recurrent-neural-networks.pdf": "\ud83d\udcc4 Summary of the Publication\nThe main themes across the provided documents include the application of deep learning in various aspects of bioinformatics and cheminformatics, such as peptide property prediction, solubility and hemolytic activity modeling, and antimicrobial peptide design. Additionally, there is a focus on the development and evaluation of predictive models, the use of web-based tools for open science, the importance of reproducibility and accessibility in research, and the utilization of serverless computing for efficient model deployment. Other themes include the integration of machine learning in drug discovery, protein engineering, and cancer prognosis analysis, as well as advancements in artificial intelligence for accelerating antibiotic discovery and predicting protein structures. Overall, the documents highlight the intersection of machine learning, bioinformatics, and cheminformatics in advancing research and innovation in various scientific domains.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\ud83d\udcdd Topics Covered in the Publication\nDeep Learning/Bioinformatics/Cheminformatics/Peptide Property Prediction/Solubility Modeling/Hemolytic Activity Modeling/Antimicrobial Peptide Design/Predictive Models/Open Science/Reproducibility/Accessibility/Serverless Computing/Drug Discovery/Protein Engineering/Cancer Prognosis/Artificial Intelligence/Antibiotic Discovery/Protein Structure Prediction\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: new materials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: screening algorithms\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: experimental methodology\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: ML algirothms\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: models\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: DSResSol (1) takes advantage of the integration of Squeeze-and-Excitation (SE)65 residual networks66 with dilated convolutional neural networks.67\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: funding\n\ud83d\udca1 Answer: Yes\n\ud83d\udd0e Supporting Sentence: Research reported inthisworkwassupported bytheNational Institute ofGeneral Medical Sciences ofthe National Institutes ofHealth underawardnumber R35GM137966.\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: material datasets\n\ud83d\udca1 Answer: No\n\ud83d\udd0e Supporting Sentence: NA\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: drug formulations explored\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: lead small-molecule drug candidates\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\n\u2753 Question: clinical trials\n\ud83d\udca1 Answer: NA\n\ud83d\udd0e Supporting Sentence: None\n\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501\u2501"}